Recent Quotes (30 days)

You have no recent quotes
chg | %

Biosyent Inc.  

(Public, CVE:RX)   Watch this stock  
Find more results for RX
8.00
+0.19 (2.43%)
Delayed:   12:07PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 7.90 - 8.09
52 week 1.45 - 8.19
Open 7.90
Vol / Avg. 28,031.00/26,091.00
Mkt cap 110.41M
P/E 54.25
Div/yield     -
EPS 0.15
Shares 13.80M
Beta 1.00
Inst. own     -

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 20.89% 24.72%
Operating margin 27.47% 31.06%
EBITD margin - 31.51%
Return on average assets 32.80% 39.57%
Return on average equity 39.83% 50.12%
CDP Score - -

Address

Suite 520, 170 Attwell Drive
TORONTO, ON M9W 5Z5
Canada
+1-905-2060013 (Phone)
+1-905-2061413 (Fax)

Website links

Description

BioSyent Inc. is a life science company that acquires or licenses products and commercializes science-based technologies that advance human health and public safety. The Company's principal business activities include the marketing of pharmaceutical products in Canada and the manufacturing and marketing of non-chemical bio- and health-friendly insecticides worldwide. BioSyent�s focuses on sourcing pharmaceutical products that have been developed and proven safe and effective; managing the regulatory process through to product registration (approval), and once approved, marketing these products in Canada. The Company, through its subsidiary, BioSyent Pharma Inc. launched FeraMAX, an oral hematinic, to the Canadian healthcare market. FeraMAX is indicated for the prevention and treatment of iron deficiency anaemia (IDA). The Company manufactures and markets a bio-friendly non-toxic product Protect-It. Protect-It is a non-chemical, food-safe grain insecticide.

Officers and directors

Rene C. Goehrum Chairman of the Board, President, Chief Executive Officer
Alfred D'Souza Chief Financial Officer
Kevin Wilson Vice President - Sales and Marketing of BioSyent Pharma Inc
Douglas R. Larson Secretary, Director
Peter D. Lockhard Independent Director
Paul R. Montador Independent Director
Milton E. Wakefield Independent Director
Stephen Wilton Independent Director